Literature DB >> 3472080

Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC.

G Carayanniotis, B H Barber.   

Abstract

The generation of strong serological responses to protein antigens in experimental animals usually requires the use of potent adjuvants, most of which cannot be used in human or veterinary vaccines because of deleterious side effects. Attempting to circumvent this problem, we have assessed an adjuvant-free antigen-delivery system based on the hypothesis that antigen coupled to monoclonal antibodies (mAbs) specific for class II major histocompatibility complex (MHC) determinants should be 'targeted' onto antigen-presenting cells, thus facilitating recognition by helper T cells. We found that the biotin-binding protein avidin could generate a serological response in mice, without adjuvant, when injected coupled to a biotinylated anti-class II MHC mAb. Equivalent amounts of avidin mixed with the non-biotinylated form of the same mAb failed to elicit a response. A targeting effect was demonstrated at low levels of injected conjugate because only mice bearing the appropriate class II antigens responded. Responses were also seen with a protein antigen other than avidin, offering a new, adjuvant-free approach to subunit vaccine construction.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3472080     DOI: 10.1038/327059a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  28 in total

1.  Anti-class II monoclonal antibody-targeted Vibrio cholerae TcpA pilin: modulation of serologic response, epitope specificity, and isotype.

Authors:  J Y Wu; R K Taylor; W F Wade
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.

Authors:  I B Rasmussen; E Lunde; T E Michaelsen; B Bogen; I Sandlie
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

3.  A potent adjuvant effect of CD40 antibody attached to antigen.

Authors:  Tom A Barr; Adele L McCormick; Jennifer Carlring; Andrew W Heath
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

4.  Antigen targeting to major histocompatibility complex class II with streptococcal mitogenic exotoxin Z-2 M1, a superantigen-based vaccine carrier.

Authors:  Fiona J Radcliff; Jacelyn M S Loh; Birgit Ha; Diana Schuhbauer; James McCluskey; John D Fraser
Journal:  Clin Vaccine Immunol       Date:  2012-02-01

5.  Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.

Authors:  H Wang; M N Griffiths; D R Burton; P Ghazal
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 6.  Improving vaccines by targeting antigens to dendritic cells.

Authors:  Ken Shortman; Mireille H Lahoud; Irina Caminschi
Journal:  Exp Mol Med       Date:  2009-02-28       Impact factor: 8.718

7.  DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.

Authors:  Gunnveig Grodeland; Siri Mjaaland; Kenneth H Roux; Agnete Brunsvik Fredriksen; Bjarne Bogen
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

Review 8.  Controlling immune responses by targeting antigens to dendritic cell subsets and B cells.

Authors:  Craig P Chappell; Natalia V Giltiay; Christiane Dresch; Edward A Clark
Journal:  Int Immunol       Date:  2013-11-27       Impact factor: 4.823

Review 9.  Dendritic cell-targeted vaccines--hope or hype?

Authors:  Wolfgang Kastenmüller; Kathrin Kastenmüller; Christian Kurts; Robert A Seder
Journal:  Nat Rev Immunol       Date:  2014-09-05       Impact factor: 53.106

10.  Generation of Immunity against Pathogens via Single-Domain Antibody-Antigen Constructs.

Authors:  Joao N Duarte; Juan J Cragnolini; Lee Kim Swee; Angelina M Bilate; Justin Bader; Jessica R Ingram; Ali Rashidfarrokhi; Tao Fang; Ariën Schiepers; Leo Hanke; Hidde L Ploegh
Journal:  J Immunol       Date:  2016-11-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.